Parkinson's disease: From human genetics to clinical trials

Science Translational Medicine

Volumn 7, Issue 305, 2015, Pages

  Van Der Brug, Marcel P ^a   Singleton, Andrew ^b   Gasser, Thomas ^c   Lewis, Patrick A ^d,e  

^a GENENTECH INC   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF READING   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; HLA DRB5 ANTIGEN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN; SOLANEZUMAB; BIOLOGICAL MARKER; DOPAMINE;

CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN GENETICS; LYSOSOME; MACROAUTOPHAGY; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; DEGENERATIVE DISEASE; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; SUBSTANTIA NIGRA;

ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DOPAMINE; DOPAMINERGIC NEURONS; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYSOSOMES; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84941795435     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa8280     Document Type: Review

References (68)

1. A. J. Lees, J. Hardy, T. Revesz, Parkinson's disease. Lancet 373, 2055-2066 (2009).
2. S. L. Kowal, T. M. Dall, R. Chakrabarti, M. V. Storm, A. Jain, The current and projected economic burden of Parkinson's disease in the United States. Mov. Disorders. 28, 311-318 (2013).
3. J. Jankovic, W. Poewe, Therapies in Parkinson's disease. Curr. Opin. Neurol. 25, 433-447 (2012).
4. W. Dauer, S. Przedborski, Parkinson's disease: Mechanisms and models. Neuron 39, 889-909 (2003).
5. J. Hardy, P. Lewis, T. Revesz, A. Lees, C. Paisan-Ruiz, The genetics of Parkinson's syndromes: A critical review. Curr. Opin. Genet. Dev. 19, 254-265 (2009).
6. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, R. L. Nussbaum, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
7. M. A. Nalls, V. Plagnol, D. G. Hernandez, M. Sharma, U. M. Sheerin, M. Saad, J. Simón-Sánchez, C. Schulte, S. Lesage, S. Sveinbjörnsdóttir, K. Stefánsson, M. Martinez, J. Hardy, P. Heutink, A. Brice, T. Gasser, A. B. Singleton, N. W. Wood - International Parkinson Disease Genomics Consortium, Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377, 641-649 (2011).
8. C. Paisan-Ruiz, P. Lewis, A. Singleton, LRRK2: Cause, risk, and mechanism. J. Parkinson's Dis. 3, 85-103 (2013).
9. C. Manzoni, P. Denny, R. C. Lovering, P. A. Lewis, Computational analysis of the LRRK2 interactome. PeerJ. 3, e778 (2015).
10. E. Kara, P. A. Lewis, H. Ling, C. Proukakis, H. Houlden, J. Hardy, α-Synuclein mutations cluster around a putative protein loop. Neurosci. Lett. 546, 67-70 (2013).
11. H. A. Lashuel, C. R. Overk, A. Oueslati, E. Masliah, The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48 (2013).
12. J. Hardy, Genetic analysis of pathways to Parkinson disease. Neuron 68, 201-206 (2010).
13. L. A. Kane, M. Lazarou, A. I. Fogel, Y. Li, K. Yamano, S. A. Sarraf, S. Banerjee, R. J. Youle, PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 205, 143-153 (2014).
14. A. Kazlauskaite, C. Kondapalli, R. Gourlay, D. G. Campbell, M. S. Ritorto, K. Hofmann, D. R. Alessi, A. Knebel, M. Trost, M. M. Muqit, Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem. J. 460, 127-139 (2014).
15. F. Koyano, K. Okatsu, H. Kosako, Y. Tamura, E. Go, M. Kimura, Y. Kimura, H. Tsuchiya, H. Yoshihara, T. Hirokawa, T. Endo, E. A. Fon, J. F. Trempe, Y. Saeki, K. Tanaka, N. Matsuda, Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510, 162-166 (2014).
16. M. Lazarou, D. A. Sliter, L. A. Kane, S. A. Sarraf, C. Wang, J. L. Burman, D. P. Sideris, A. I. Fogel, R. J. Youle, The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524, 309-314 (2015).
17. B. Bingol, J. S. Tea, L. Phu, M. Reichelt, C. E. Bakalarski, Q. Song, O. Foreman, D. S. Kirkpatrick, M. Sheng, The mitochondrial deubiquitinase USP30 opposes parkinmediated mitophagy. Nature 510, 370-375 (2014).
18. J. Yun, R. Puri, H. Yang, M. A. Lizzio, C. Wu, Z. H. Sheng, M. Guo, MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin. eLife 3, e01958 (2014).
19. H. Houlden, A. B. Singleton, The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124, 325-338 (2012).
20. C. Manzoni, P. A. Lewis, Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies. FASEB J. 27, 3424-3429 (2013).
21. A. R. Winslow, C. W. Chen, S. Corrochano, A. Acevedo-Arozena, D. E. Gordon, A. A. Peden, M. Lichtenberg, F. M. Menzies, B. Ravikumar, S. Imarisio, S. Brown, C. J. O'Kane, D. C. Rubinsztein, α-Synuclein impairs macroautophagy: Implications for Parkinson's disease. J. Cell Biol. 190, 1023-1037 (2010).
22. A. M. Cuervo, L. Stefanis, R. Fredenburg, P. T. Lansbury, D. Sulzer, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295 (2004).
23. S. J. Orenstein, S. H. Kuo, I. Tasset, E. Arias, H. Koga, I. Fernandez-Carasa, E. Cortes, L. S. Honig, W. Dauer, A. Consiglio, A. Raya, D. Sulzer, A. M. Cuervo, Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394-406 (2013).
24. C. Manzoni, A. Mamais, S. Dihanich, R. Abeti, M. P. Soutar, H. Plun-Favreau, P. Giunti, S. A. Tooze, R. Bandopadhyay, P. A. Lewis, Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim. Biophys. Acta 1833, 2900-2910 (2013).
25. J. Alegre-Abarrategui, H. Christian, M. M. Lufino, R. Mutihac, L. L. Venda, O. Ansorge, R. Wade-Martins, LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 18, 4022-4034 (2009).
26. A. Beilina, I. N. Rudenko, A. Kaganovich, L. Civiero, H. Chau, S. K. Kalia, L. V. Kalia, E. Lobbestael, R. Chia, K. Ndukwe, J. Ding, M. A. Nalls, International Parkinson's Disease Genomics Consortium; North American Brain Expression Consortium, M. Olszewski, D. N. Hauser, R. Kumaran, A. M. Lozano, V. Baekelandt, L. E. Greene, J. M. Taymans, E. Greggio, M. R. Cookson. Proc. Natl. Acad. Sci. U. S. A. 111, 2626-2631 (2014).
27. E. Zavodszky, M. N. Seaman, K. Moreau, M. Jimenez-Sanchez, S. Y. Breusegem, M. E. Harbour, D. C. Rubinsztein, Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy. Nat. Commun. 5, 3828 (2014).
28. E. Sidransky, G. Lopez, The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986-998 (2012).
29. J. R. Mazzulli, Y. H. Xu, Y. Sun, A. L. Knight, P. J. McLean, G. A. Caldwell, E. Sidransky, G. A. Grabowski, D. Krainc, Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011).
30. M. E. Gegg, D. Burke, S. J. Heales, J. M. Cooper, J. Hardy, N. W. Wood, A. H. Schapira, Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455-463 (2012).
31. J. H. Choi, B. Stubblefield, M. R. Cookson, E. Goldin, A. Velayati, N. Tayebi, E. Sidransky, Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol. Genet. Metab. 104, 185-188 (2011).
32. T. L. Yap, J. M. Gruschus, A. Velayati, W. Westbroek, E. Goldin, N. Moaven, E. Sidransky, J. C. Lee, Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080-28088 (2011).
33. P. J. Schultheis, S. M. Fleming, A. K. Clippinger, J. Lewis, T. Tsunemi, B. Giasson, D. W. Dickson, J. R. Mazzulli, M. E. Bardgett, K. L. Haik, O. Ekhator, A. K. Chava, J. Howard, M. Gannon, E. Hofman, Y. Chen, V. Prasad, S. C. Linn, R. J. Tamargo, W. Westbroek, E. Sidransky, D. Krainc, G. E. Shull, Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22, 2067-2082 (2013).
34. B. Dehay, A. Ramirez, M. Martinez-Vicente, C. Perier, M. H. Canron, E. Doudnikof, A. Vital, M. Vila, C. Klein, E. Bezard, Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 109, 9611-9616 (2012).
35. M. Usenovic, E. Tresse, J. R. Mazzulli, J. P. Taylor, D. Krainc, Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J. Neuroscience 32, 4240-4246 (2012).
36. D. A. MacLeod, H. Rhinn, T. Kuwahara, A. Zolin, G. Di Paolo, B. D. McCabe, K. S. Marder, L. S. Honig, L. N. Clark, S. A. Small, A. Abeliovich, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425-439 (2013).
37. Y. Lee, S. S. Karuppagounder, J. H. Shin, Y. I. Lee, H. S. Ko, D. Swing, H. Jiang, S. U. Kang, B. D. Lee, H. C. Kang, D. Kim, L. Tessarollo, V. L. Dawson, T. M. Dawson, Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. Neurosci. 16, 1392-1400 (2013).
38. J. H. Shin, H. S. Ko, H. Kang, Y. Lee, Y. I. Lee, O. Pletinkova, J. C. Troconso, V. L. Dawson, T. M. Dawson, PARIS (ZNF746) repression of PGC-1 α contributes to neurodegeneration in Parkinson's disease. Cell 144, 689-702 (2011).
39. S. Wray, P. A. Lewis, A tangled web-Tau and sporadic Parkinson's disease. Front. Psychiat. 1, 150 (2010).
40. E. Angot, J. A. Steiner, C. Hansen, J. Y Li, P. Brundin, Are synucleinopathies prion-like disorders? Lancet Neurol. 9, 1128-1138 (2010).
41. L. M. Ittner, J. Götz, Amyloid-ß and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65-72 (2011).
42. P. Holmans, V. Moskvina, L. Jones, M. Sharma, A. Vedernikov, F. Buchel, M. Saad, J. M. Bras, F. Bettella, N. Nicolaou, J. Simón-Sánchez, F. Mittag, J. R. Gibbs, C. Schulte, A. Durr, R. Guerreiro, D. Hernandez, A. Brice, H. Stefánsson, K. Majamaa, T. Gasser, P. Heutink, N. W. Wood, M. Martinez, A. B. Singleton, M. A. Nalls, J. Hardy, H. R. Morris, N. M. Williams, International Parkinson's Disease Genomics Consortium, A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum. Mol. Genet. 22, 1039-1049 (2013).
43. F. Fahrenholz, R. Postina, Alpha-secretase activation-an approach to Alzheimer's disease therapy. Neurodegener. Dis. 3, 255-261 (2006).
44. P. C. Kandalepas, R. Vassar, Identification and biology of ß-secretase. J. Neurochem. 120(suppl. 1), 55-61 (2012).
45. B. De Strooper, R. Vassar, T. Golde, The secretases: Enzymes with therapeutic potential in Alzheimer disease. Neurology 6, 99-107 (2010).
46. R. S. Doody, R. Raman, M. Farlow, T. Iwatsubo, B. Vellas, S. Jofe, K. Kieburtz, F. He, X. Sun, R. G. Thomas, P. S. Aisen, E. Siemers, G. Sethuraman, R. Mohs, Alzheimer's Disease Cooperative Study Steering Committee, Semagacestat Study Group, A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350 (2013).
47. W. Poewe, A. Antonini, Novel formulations and modes of delivery of levodopa. Movement Disorders 30, 114-120 (2015).
48. S. H. Fox et al., The Movement Disorder Society evidencebased medicine review update: Treatments for the motor symptoms of Parkinson's disease. Movement Disorders 26 suppl.3, S2-S41 (2011).
49. J. M. Taymans, Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? Expert Opin. Therap. Patents 24, 727-730 (2014).
50. H. T. Tran, C. H. Chung, M. Iba, B. Zhang, J. Q. Trojanowski, K. C. Luk, V. M. Lee,α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Reports 7, 2054-2065 (2014).
51. A. McNeill, J. Magalhaes, C. Shen, K. Y Chau, D. Hughes, A. Mehta, T. Foltynie, J. M. Cooper, A. Y Abramov, M. Gegg, A. H. Schapira, Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481-1495 (2014).
52. M. Mandler, E. Valera, E. Rockenstein, H. Weninger, C. Patrick, A. Adame, R. Santic, S. Meindl, B. Vigl, O. Smrzka, A. Schneeberger, F. Mattner, E. Masliah, Next-generation active immunization approach for synucleinopathies: Implications for Parkinson's disease clinical trials. Acta Neuropathol. 127, 861-879 (2014).
53. R. Pahwa, K. E. Lyons, R. A. Hauser, S. Fahn, J. Jankovic, E. Pourcher, A. Hsu, M. O'Connell, S. Kell, S. GuptaAPEX-PD Investigators, Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat. Disord. 20, 142-148 (2014).
54. T. C. Vu, J. G. Nutt, N. H. Holford, Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br. J. Clin. Pharmacol. 74, 267-283 (2012).
55. E. R. Siemers, K. L. Sundell, C. Carlson, M. Case, G. Sethuraman, H. Liu-Seifert, S. A. Dowsett, M. J. Pontecorvo, R. A. Dean, R. Demattos, Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 10.1016/j.jalz.2015.06.1893 (2015).
56. S. J. Pocock, T. C. Clayton, D. G. Altman, Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls. Lancet 359, 1686-1689 (2002).
57. A. Mullard, Sting of Alzheimer's failures of set by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657-660 (2012).
58. R. J. Bateman, C. Xiong, T. L. Benzinger, A. M. Fagan, A. Goate, N. C. Fox, D. S. Marcus, N. J. Cairns, X. Xie, T. M. Blazey, D. M. Holtzman, A. Santacruz, V. Buckles, A. Oliver, K. Moulder, P. S. Aisen, B. Ghetti, W. E. Klunk, E. McDade, R. N. Martins, C. L. Masters, R. Mayeux, J. M. Ringman, M. N. Rossor, P. R. Schofield, R. A. Sperling, S. Salloway, C. Morris Dominantly Inherited Alzheimer Network, Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804 (2012).
59. D. G. Healy, M. Falchi, S. S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C. P. Zabetian, S. Goldwurm, J. J. Ferreira, E. Tolosa, D. M. Kay, C. Klein, D. R. Williams, C. Marras, A. E. Lang, Z. K. Wszolek, J. Berciano, A. H. Schapira, T. Lynch, K. P. Bhatia, T. Gasser, A. J. Lees, N. W. Wood, International LRRK2 Consortium, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 7, 583-590 (2008).
60. S. Lesage, A. Dürr, M. Tazir, E. Lohmann, A. L. Leutenegger, S. Janin, P. Pollak, A. BriceFrench Parkinson's Disease Genetics Study Group, LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422-423 (2006).
61. E. Sidransky, M. A. Nalls, J. O. Aasly, J. Aharon-Peretz, G. Annesi, E. R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, C. M. Chen, L. N. Clark, C. Condroyer, E. V. De Marco, A. Dürr, M. J. Eblan, S. Fahn, M. J. Farrer, H. C. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffth, T. Gurevich, C. Januario, P. Kropp, A. E. Lang, G. J. Lee-Chen, S. Lesage, K. Marder, I. F. Mata, A. Mirelman, J. Mitsui, I. Mizuta, G. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, L. V. Pereira, A. Quattrone, E. Rogaeva, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samaddar, C. Schulte, M. Sharma, A. Singleton, M. Spitz, E. K. Tan, N. Tayebi, T. Toda, A. R. Troiano, S. Tsuji, M. Wittstock, T. G. Wolfsberg, Y. R. Wu, C. P. Zabetian, Y. Zhao, S. G. Ziegler, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651-1661 (2009).
62. H. Q. Rana, M. Balwani, L. Bier, R. N. Alcalay, Age-specific Parkinson disease risk in GBA mutation carriers: Information for genetic counseling. Genetics Med. 15, 146-149 (2013).
63. R. B. Postuma, D. Aarsland, P. Barone, D. J. Burn, C. H. Hawkes, W. Oertel, T. Ziemssen, Identifying prodromal Parkinson's disease: Pre-motor disorders in Parkinson's disease. Movement Disorders 27, 617-626 (2012).
64. A. H. Schapira, Recent developments in biomarkers in Parkinson disease. Curr. Opin. Neurol. 26, 395-400 (2013).
65. I. Parkinson, The Parkinson Progression Marker Initiative (PPMI), Prog. Neurobiol. 95, 629-635 (2011).
66. M. A. Nalls, C. Y. McLean, J. Rick, S. Eberly, S. J. Hutten, K. Gwinn, M. Sutherland, M. Martinez, P. Heutink, N. M. Williams, J. Hardy, T. Gasser, A. Brice, T. R. Price, A. Nicolas, M. F. Keller, C. Molony, J. R. Gibbs, A. Chen-Plotkin, E. Suh, C. Letson, M. S. Fiandaca, M. Mapstone, H. J. Federof, A. J. Noyce, H. Morris, V. M. Van Deerlin, D. Weintraub, C. Zabetian, D. G. Hernandez, S. Lesage, M. Mullins, E. D. Conley, C. A. Northover, M. Frasier, K. Marek, A. G. Day-Williams, D. J. Stone, J. P. Ioannidis, A. B. Singleton, Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators, Diagnosis of Parkinson's disease on the basis oficlinical and genetic classification: A population-based modelling study. Lancet Neurol. (2015). 10.1016/S1474-4422 (15) 00178-7
67. J. M. Taymans, A. Nkiliza, M. C. Chartier-Harlin, Deregulation of protein translation control, a potential gamechanging hypothesis for Parkinson's disease pathogenesis. Trends Mol. Med. 21, 466-472 (2015).
68. R. N. Fuji, M. Flagella, M. Baca, M. A. Baptista, J. Brodbeck, B. K. Chan, B. K. Fiske, L. Honigberg, A. M. Jubb, P. Katavolos, D. W. Lee, S.-C. Lewin-Koh, T. Lin, X. Liu, S. Liu, J. P. Lyssikatos, J. O'Mahony, M. Reichelt, M. Roose-Girma, Z. Sheng, T. Sherer, A. Smith, M. Solon, Z. K. Sweeney, J. Tarrant, A. Urkowitz, S. Warming, M. Yaylaoglu, S. Zhang, H. Zhu, A. A. Estrada, R. J. Watts, Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med. 7, 273ra15 (2015).